Danske Bank A S Has $56.27 Million Stock Position in Becton, Dickinson and Company $BDX

Key Points

• Danske Bank increased its stake in Becton, Dickinson & Company by 56.9% during Q4 to 289,926 shares worth about $56.27 million, representing roughly 0.10% of the company.
• BDX beat EPS expectations ($2.91 vs. $2.81) but missed revenue estimates ($4.49B vs. $5.15B), set FY2026 guidance of $12.35–12.65 EPS, authorized a $10 million share buyback and declared a $1.05 quarterly dividend (≈2.8% yield).
• Director Bertram L. Scott recently sold shares and insiders have sold 1,102 shares in the last 90 days; institutional ownership is high at 86.97% while corporate insiders own 0.40%, and analysts carry a consensus "Hold" rating with a $189.08 target.

Danske Bank A S grew its stake in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 56.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 289,926 shares of the medical instruments supplier's stock after purchasing an additional 105,091 shares during the period. Danske Bank A S owned approximately 0.10% of Becton, Dickinson and Company worth $56,266,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. SOA Wealth Advisors LLC. raised its holdings in shares of Becton, Dickinson and Company by 256.8% during the third quarter. SOA Wealth Advisors LLC. now owns 132 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 95 shares during the period. Activest Wealth Management raised its holdings in shares of Becton, Dickinson and Company by 285.3% during the third quarter. Activest Wealth Management now owns 131 shares of the medical instruments supplier's stock valued at $25,000 after purchasing an additional 97 shares during the period. Imprint Wealth LLC acquired a new position in shares of Becton, Dickinson and Company during the third quarter valued at about $25,000. Steph & Co. raised its holdings in shares of Becton, Dickinson and Company by 95.6% during the fourth quarter. Steph & Co. now owns 133 shares of the medical instruments supplier's stock valued at $26,000 after purchasing an additional 65 shares during the period. Finally, Cornerstone Planning Group LLC raised its holdings in shares of Becton, Dickinson and Company by 463.3% during the third quarter. Cornerstone Planning Group LLC now owns 169 shares of the medical instruments supplier's stock valued at $30,000 after purchasing an additional 139 shares during the period. Institutional investors and hedge funds own 86.97% of the company's stock.

Insider Transactions at Becton, Dickinson and Company

In other Becton, Dickinson and Company news, Director Bertram L. Scott sold 953 shares of the company's stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $182.61, for a total value of $174,027.33. Following the completion of the sale, the director directly owned 36,763 shares of the company's stock, valued at approximately $6,713,291.43. This represents a 2.53% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last ninety days, insiders have sold 1,102 shares of company stock valued at $198,909. Corporate insiders own 0.40% of the company's stock.

Becton, Dickinson and Company Trading Up 0.3%

NYSE:BDX opened at $149.41 on Friday. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.05 and a quick ratio of 0.58. The firm has a 50-day moving average of $160.69 and a 200-day moving average of $181.99. The company has a market cap of $42.54 billion, a PE ratio of 24.37, a PEG ratio of 10.63 and a beta of 0.22. Becton, Dickinson and Company has a one year low of $127.59 and a one year high of $187.35.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings data on Monday, February 9th. The medical instruments supplier reported $2.91 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.81 by $0.10. Becton, Dickinson and Company had a net margin of 8.01% and a return on equity of 15.76%. The business had revenue of $4.49 billion during the quarter, compared to the consensus estimate of $5.15 billion. During the same period in the prior year, the firm posted $3.43 EPS. The firm's quarterly revenue was up 1.6% compared to the same quarter last year. Becton, Dickinson and Company has set its FY 2026 guidance at 12.350-12.650 EPS. As a group, equities research analysts expect that Becton, Dickinson and Company will post 12.52 EPS for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has initiated a share buyback program on Tuesday, January 27th that permits the company to repurchase $10.00 million in shares. This repurchase authorization permits the medical instruments supplier to purchase up to 0% of its shares through open market purchases. Shares repurchase programs are often a sign that the company's board believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 30th. Shareholders of record on Tuesday, June 9th will be given a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.8%. The ex-dividend date of this dividend is Tuesday, June 9th. Becton, Dickinson and Company's dividend payout ratio is presently 68.52%.

Analysts Set New Price Targets

BDX has been the topic of several research reports. TD Cowen upped their price objective on shares of Becton, Dickinson and Company from $183.00 to $189.00 and gave the company a "hold" rating in a report on Wednesday, February 11th. Piper Sandler decreased their target price on shares of Becton, Dickinson and Company from $170.00 to $159.00 and set a "neutral" rating for the company in a research report on Friday, April 17th. Bank of America boosted their target price on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the stock a "neutral" rating in a research report on Monday, January 5th. Royal Bank Of Canada set a $175.00 target price on shares of Becton, Dickinson and Company in a research report on Tuesday, April 14th. Finally, Barclays started coverage on shares of Becton, Dickinson and Company in a research report on Tuesday, February 10th. They set an "overweight" rating and a $202.00 target price for the company. Six analysts have rated the stock with a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, Becton, Dickinson and Company currently has an average rating of "Hold" and a consensus price target of $189.08.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD's products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company's operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD's product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.